Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1694-1702

  Ko, Yu ^a   Malone, Daniel C ^a   Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antimus carinic agents; Cost effectiveness analysis; Darifenacin; Decision analytic model; Decision analysis model; OAB; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; COMORBIDITY; COST OF ILLNESS; DECISION ANALYSIS MODEL; DECISION MAKING; DEPRESSION; DRUG COST; DRUG FORMULATION; DRUG WITHDRAWAL; EVALUATION; EXTENDED RELEASE FORMULATION; FRACTURE; HUMAN; IMMEDIATE RELEASE FORMULATION; MEDLINE; MONEY; OVERACTIVE BLADDER; PROBABILITY; SKIN INFECTION; URINARY TRACT INFECTION;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSAGE FORMS; HUMANS; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33845364076     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1694     Document Type: Article

References (51)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
2. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(5 suppl 1):7-12.
3. Newman DK, Giovannini D. The overactive bladder: a nursing perspective. Am J Nurs 2002;102:36-45.
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
5. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8.
6. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002;8:S598-607.
7. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005;25:511-19.
8. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-9.
9. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
10. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs 2004;64:885-912.
11. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS oxybutynin study group. J Urol 1999;161:1809-12.
12. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL study group. Obstet Gynecol 2000;95:718-21.
13. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6.
14. Davila GW. Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin Pharmacother 2003;4:2315-24.
15. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
16. Couture JA, Valiquette L. Urinary incontinence. Ann Pharmacother 2000;34:646-55.
17. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5.
18. Freeman R, Hill S, Millard R, Slack M, Sutherst J. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003;102:605-11.
19. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-9.
20. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60.
21. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(suppl 6A):90-6.
22. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
23. Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001;19:141-7.
24. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161:1551-5.
25. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 2001;98:97-102.
26. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
27. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505.
28. Chilman-Blair K, Bosch JL. Solifenacin: treatment of overactive bladder. Drugs Today 2004;40:343-53.
29. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 2004;5:359-67.
30. Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging 2004;21:885-92.
31. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9.
32. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6.
33. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001.
34. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
35. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
36. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71-7.
37. Frohlich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther 2002;40:295-303.
38. Alloussi S, Laval K-U, Eckert R, et al. Trospium chloride in patients with motor urge syndrome: a double-blind, randomised, multicenter, placebo-controlled study. J Clin Res 1998;1:439-51.
39. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-15.
40. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9.
41. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42.
42. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol 1999;162:82-4.
43. Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002;8:343-52.
44. Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13:88-94.
45. Guest JF, Abegunde D, Ruiz F. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Invest 2004;24:305-21.
46. Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am J Manag Care 2005;11:S150-7.
47. Hall JA, Nelson MA, Meyer JW, Williamson T, Wagner S. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag Care Interface 2001;14:69-75.
48. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005;11:S140-9.
49. Getsios D, Caro JJ, Ishak KJ, et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin Drug Invest 2004;24:81-8.
50. Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther 2004;26:431-8.
51. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004;22:1047-59.